{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T15:20:01Z","timestamp":1791559201880,"version":"4.3.4"},"reference-count":21,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["ajo.com","clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Ophthalmology"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1016\/j.ajo.2023.07.022","type":"journal-article","created":{"date-parts":[[2023,7,28]],"date-time":"2023-07-28T21:18:40Z","timestamp":1690579120000},"page":"20-26","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Outcomes of Intentionally Suspending Treatment in Eyes With Advanced Neovascular Age-Related Macular Degeneration"],"prefix":"10.1016","volume":"256","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2469-5305","authenticated-orcid":false,"given":"Katherine C.","family":"Awh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5818-9083","authenticated-orcid":false,"given":"Raziyeh","family":"Mahmoudzadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8654-2876","authenticated-orcid":false,"given":"Mirataollah","family":"Salabati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0634-3429","authenticated-orcid":false,"given":"Hana A.","family":"Mansour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Bechay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Magagna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carl D.","family":"Regillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3921-608X","authenticated-orcid":false,"given":"Allen C.","family":"Ho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunir J.","family":"Garg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2761-4219","authenticated-orcid":false,"given":"Jason","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.ajo.2023.07.022_bib0001","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1016\/j.ophtha.2012.03.053","article-title":"Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results","volume":"119","author":"Martin","year":"2012","journal-title":"Ophthalmology"},{"issue":"14","key":"10.1016\/j.ajo.2023.07.022_bib0002","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1056\/NEJMoa054481","article-title":"Ranibizumab for neovascular age-related macular degeneration","volume":"355","author":"Rosenfeld","year":"2006","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.ajo.2023.07.022_bib0003","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1016\/j.ophtha.2012.09.006","article-title":"Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration","volume":"119","author":"Heier","year":"2012","journal-title":"Ophthalmology"},{"issue":"6","key":"10.1016\/j.ajo.2023.07.022_bib0004","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/j.ophtha.2019.01.013","article-title":"Canadian treat-and-extend analysis trial with ranibizumab in patients with neovascular age-related macular disease: one-year results of the Randomized Canadian Treat-and-Extend Analysis Trial with Ranibizumab Study","volume":"126","author":"Kertes","year":"2019","journal-title":"Ophthalmology"},{"issue":"8","key":"10.1016\/j.ajo.2023.07.022_bib0005","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/j.oret.2019.05.013","article-title":"Outcomes of suspending VEGF inhibitors for neovascular age-related macular degeneration when lesions have been inactive for 3 months","volume":"3","author":"Nguyen","year":"2019","journal-title":"Ophthalmol Retina"},{"issue":"1","key":"10.1016\/j.ajo.2023.07.022_bib0006","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1097\/IAE.0000000000001923","article-title":"Exit strategy in a treat-and-extend regimen for exudative age-related macular degeneration","volume":"39","author":"Arendt","year":"2019","journal-title":"Retina (Philadelphia, Pa)"},{"issue":"1","key":"10.1016\/j.ajo.2023.07.022_bib0007","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.ophtha.2007.03.008","article-title":"The natural history and prognosis of neovascular age-related macular degeneration: a systematic review of the literature and meta-analysis","volume":"115","author":"Wong","year":"2008","journal-title":"Ophthalmology"},{"issue":"11","key":"10.1016\/j.ajo.2023.07.022_bib0008","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1001\/archopht.1988.01060140705039","article-title":"Natural course of poorly defined choroidal neovascularization associated with macular degeneration","volume":"106","author":"Bressler","year":"1988","journal-title":"Arch Ophthalmol"},{"issue":"7","key":"10.1016\/j.ajo.2023.07.022_bib0009","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1016\/j.ophtha.2018.01.012","article-title":"Consistent long-term therapy of neovascular age-related macular degeneration managed by 50 or more anti-VEGF injections using a treat-extend-stop protocol","volume":"125","author":"Adrean","year":"2018","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ajo.2023.07.022_bib0010","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.2147\/OPTH.S256009","article-title":"Correlation of baseline visual acuity with outcomes of treatment with anti-VEGF in neovascular age-related macular degeneration","volume":"14","author":"Veluswamy","year":"2020","journal-title":"Clin Ophthalmol"},{"issue":"7","key":"10.1016\/j.ajo.2023.07.022_bib0011","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1001\/archophthalmol.2011.2617","article-title":"Intravitreal bevacizumab in advanced-stage neovascular age-related macular degeneration with visual acuity lower than 20\/200 intravitreal bevacizumab in advanced-stage neovascular age-related macular degeneration with visual acuity lower than 20\/200","volume":"130","author":"Parodi","year":"2012","journal-title":"Arch Ophthalmol"},{"issue":"8","key":"10.1016\/j.ajo.2023.07.022_bib0012","doi-asserted-by":"crossref","first-page":"e697","DOI":"10.1111\/aos.12417","article-title":"Consequences of long-term discontinuation of vascular endothelial growth factor inhibitor therapy in the patients with neovascular age-related macular degeneration","volume":"92","author":"Vaze","year":"2014","journal-title":"Acta Ophthalmol"},{"issue":"5","key":"10.1016\/j.ajo.2023.07.022_bib0013","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1097\/IAE.0000000000001282","article-title":"Long-term outcomes and incidence of recurrence of neovascularization in treated exudative age-related macular degeneration","volume":"37","author":"Haddad","year":"2017","journal-title":"Retina (Philadelphia, Pa)"},{"issue":"3","key":"10.1016\/j.ajo.2023.07.022_bib0014","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1097\/IAE.0000000000001572","article-title":"Long-term remission of neovascular age-related macular degeneration with as-needed anti-vascular endothelial growth factor therapy","volume":"38","author":"Muftuoglu","year":"2018","journal-title":"Retina (Philadelphia, Pa)"},{"key":"10.1016\/j.ajo.2023.07.022_bib0015","article-title":"Baseline predictors of visual acuity outcome in patients with wet age-related macular degeneration","volume":"2018","author":"Zhang","year":"2018","journal-title":"Biomed Res Int"},{"issue":"8","key":"10.1016\/j.ajo.2023.07.022_bib0016","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/j.oret.2019.04.013","article-title":"Long-term management of neovascular age-related macular degeneration: to suspend or not to suspend?","volume":"3","author":"Khurana","year":"2019","journal-title":"Ophthalmol Retina"},{"issue":"12","key":"10.1016\/j.ajo.2023.07.022_bib0017","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1016\/j.ophtha.2015.08.014","article-title":"Scheduled versus pro re nata dosing in the VIEW Trials","volume":"122","author":"Richard","year":"2015","journal-title":"Ophthalmology"},{"issue":"1","key":"10.1016\/j.ajo.2023.07.022_bib0018","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.ophtha.2015.09.018","article-title":"Ranibizumab or bevacizumab for neovascular age-related macular degeneration according to the Lucentis compared to Avastin study treat-and-extend protocol: two-year results","volume":"123","author":"Berg","year":"2016","journal-title":"Ophthalmology"},{"issue":"12","key":"10.1016\/j.ajo.2023.07.022_bib0019","doi-asserted-by":"crossref","first-page":"2630","DOI":"10.1016\/j.ophtha.2013.05.018","article-title":"A 4-year longitudinal study of 555 patients treated with ranibizumab for neovascular age-related macular degeneration","volume":"120","author":"Rasmussen","year":"2013","journal-title":"Ophthalmology"},{"issue":"4","key":"10.1016\/j.ajo.2023.07.022_bib0020","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1038\/s41433-021-01562-6","article-title":"Continued anti-VEGF treatment does not prevent recurrences in eyes with stable neovascular age-related macular degeneration using a treat-and-extend regimen: a retrospective case series","volume":"36","author":"Garweg","year":"2022","journal-title":"Eye"},{"issue":"6","key":"10.1016\/j.ajo.2023.07.022_bib0021","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1097\/IAE.0000000000002713","article-title":"Suspending treatment of neovascular age-related macular degeneration in cases of futility","volume":"40","author":"Wong","year":"2020","journal-title":"Retina (Philadelphia, Pa)"}],"container-title":["American Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000293942300301X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000293942300301X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,31]],"date-time":"2024-05-31T19:52:20Z","timestamp":1717185140000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S000293942300301X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":21,"alternative-id":["S000293942300301X"],"URL":"https:\/\/doi.org\/10.1016\/j.ajo.2023.07.022","relation":{},"ISSN":["0002-9394"],"issn-type":[{"value":"0002-9394","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Outcomes of Intentionally Suspending Treatment in Eyes With Advanced Neovascular Age-Related Macular Degeneration","name":"articletitle","label":"Article Title"},{"value":"American Journal of Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajo.2023.07.022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}